Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Oncology · Extranodal nasal NK/T-cell lymphoma

Your Biology and Pathology Report

At a Glance

A complete Extranodal nasal NK/T-cell lymphoma (ENKTL) pathology report must confirm the cancer cells are infected with the Epstein-Barr virus using an EBER-ISH test. It should also evaluate specific markers like CD56 and cytoplasmic CD3 to definitively diagnose the disease.

Your pathology report is the definitive “map” of your diagnosis. For Extranodal nasal NK/T-cell lymphoma (ENKTL), this report must confirm two main things: that the cells are cancerous white blood cells (NK or T cells) and that they are infected with the Epstein-Barr virus (EBV) [1][2].

The Biology: How EBV “Hijacks” Your Cells

ENKTL begins when the Epstein-Barr virus infects mature Natural Killer (NK) cells or T cells—both are types of white blood cells that normally protect the body [3][4].

The virus doesn’t just sit there; it “hijacks” the cell using a protein called LMP1 [5]. This protein acts like a broken light switch that is stuck in the “on” position, constantly signaling the cell to grow, multiply, and ignore the body’s natural signals to die [6][7]. This viral-driven process transforms healthy immune cells into aggressive lymphoma cells [4].

Decoding the Pathology Report

Pathologists use a process called Immunohistochemistry (IHC)—applying special stains to your tissue sample to see which proteins are present. For ENKTL, your report should ideally show a specific “protein fingerprint” [2].

Marker What it means Expected in ENKTL
EBER-ISH Tests for EBV inside the cells Positive (Essential for diagnosis) [1]
CD56 A marker for Natural Killer (NK) cells Positive (in most cases) [3]
Cytoplasmic CD3 A marker inside the cell body Positive [2]
Surface CD3 A marker on the cell’s outer shell Negative (usually) [2]
Granzyme B / TIA-1 “Cytotoxic” molecules used to kill targets Positive [2][8]

Why the “Surface” vs. “Cytoplasmic” CD3 matters:
Normal T cells have the CD3 protein on their surface. In ENKTL, the protein is usually trapped inside the cell (the cytoplasm). This specific pattern is one of the biggest clues pathologists use to distinguish ENKTL from other types of lymphoma [2][8].

The Pathology Completeness Checklist

A “complete” pathology report for ENKTL should address several key areas to ensure an accurate diagnosis and rule out “look-alike” conditions like B-cell lymphomas or non-cancerous infections [1][9]. Ensure your report includes:

  • [ ] EBER-ISH Result: This is the single most important test to confirm the EBV link [1].
  • [ ] Lineage Markers: Specifically mentions CD56 and CD3 (both cytoplasmic and surface) [2].
  • [ ] Cytotoxic Markers: Tests for proteins like TIA-1, Granzyme B, or Perforin, which confirm the “killer” nature of the cells [2][8].
  • [ ] Description of Architecture: Mentions angiocentricity (cells surrounding blood vessels) or angioinvasion (cells invading blood vessels) [2].
  • [ ] Exclusion of B-cells: Mentions markers like CD20 are negative, proving the cancer is not a B-cell lymphoma [1][10].

If your report mentions extensive necrosis (large areas of dead tissue), it means the cancer is destroying the tissue so quickly that it’s hard for the pathologist to find living cells to test [11]. In these cases, your doctor may need to perform a second, deeper biopsy to ensure they have enough healthy “cancer” tissue to run all the tests on the checklist above [11][12].

Common questions in this guide

Why is the EBER-ISH test so important for an ENKTL diagnosis?
The EBER-ISH test looks for the Epstein-Barr virus inside the cancer cells. Because ENKTL is driven by this virus hijacking healthy immune cells, a positive EBER-ISH result is absolutely essential to confirm the diagnosis.
What does 'extensive necrosis' mean on my pathology report?
Necrosis refers to large areas of dead tissue. In ENKTL, the cancer can destroy surrounding tissue so quickly that it leaves behind mostly dead cells. If your biopsy shows extensive necrosis, your doctor may need to perform a second procedure to get a clear sample of living cancer cells for testing.
Why is CD3 positive in the cytoplasm but negative on the surface?
Normal T cells have the CD3 protein on their outer surface. In ENKTL, this protein is usually trapped inside the cell body, known as the cytoplasm. This specific inside-out pattern is a major clue that helps pathologists distinguish ENKTL from other types of lymphoma.
What do angiocentricity and angioinvasion mean?
These terms describe how the lymphoma cells interact with your blood vessels. Angiocentricity means the cancer cells are surrounding the blood vessels, while angioinvasion means they are actively invading them. This behavior restricts blood flow and causes tissue damage.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does the pathology report specify if the cells are NK-cell or T-cell lineage, and was a TCR gene rearrangement test performed?
  2. 2.Was the EBER-ISH stain strong and present in the majority of the tumor cells?
  3. 3.The report mentions "necrosis"—was the sample large enough to see the underlying cancer cells clearly?
  4. 4.Can you explain why my CD3 result is positive in the "cytoplasm" but negative on the "surface"?
  5. 5.Does my report show "angiocentricity," and how does that relate to the tissue damage I’m experiencing?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Peripheral T cell lymphoma of the nasopharynx with expansion of EBV-positive B cells masquerading as an extranodal NK/T cell lymphoma, nasal type.

    Kim HN, Kim DS, Jeon MJ, et al.

    Virchows Archiv : an international journal of pathology 2022; (481(1)):125-129 doi:10.1007/s00428-021-03240-0.

    PMID: 34997312
  2. 2

    The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.

    Kim H, Ko YH

    Life (Basel, Switzerland) 2022; (12(1)) doi:10.3390/life12010073.

    PMID: 35054466
  3. 3

    Extranodal NK/T cell lymphoma and aggressive NK cell leukaemia: evidence for their origin on CD56+bright CD16-/+dim NK cells.

    Lima M

    Pathology 2015; (47(6)):503-14 doi:10.1097/PAT.0000000000000275.

    PMID: 26166665
  4. 4

    Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.

    Haverkos BM, Pan Z, Gru AA, et al.

    Current hematologic malignancy reports 2016; (11(6)):514-527 doi:10.1007/s11899-016-0355-9.

    PMID: 27778143
  5. 5

    A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway.

    Mao Y, Wang J, Zhang M, et al.

    Oncotarget 2017; (8(7)):10954-10965 doi:10.18632/oncotarget.14032.

    PMID: 28009988
  6. 6

    Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders.

    de Mel S, Tan JZ, Jeyasekharan AD, et al.

    Frontiers in pediatrics 2018; (6()):405 doi:10.3389/fped.2018.00405.

    PMID: 30705877
  7. 7

    Association between Epstein-Barr virus LMP-1 and Hodgkin lymphoma LMP-1 mechanisms in Hodgkin lymphoma development.

    Oliveira LOD, Costa IB, Quaresma JAS

    Reviews in medical virology 2024; (34(4)):e2561 doi:10.1002/rmv.2561.

    PMID: 38877989
  8. 8

    Diagnosis and management of extranodal NK/T cell lymphoma nasal type.

    Tse E, Kwong YL

    Expert review of hematology 2016; (9(9)):861-71 doi:10.1080/17474086.2016.1206465.

    PMID: 27347812
  9. 9

    EBV-Driven NK/T-Cell Lymphoproliferative Disorders: Clinical Diversity and Molecular Insights.

    Luniewski A, Chaudhary S, Goldfarb A, Obiorah IE

    Lymphatics 2026; (4(1)) doi:10.3390/lymphatics4010007.

    PMID: 41657941
  10. 10

    EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management.

    Malpica L, Marques-Piubelli ML, Beltran BE, et al.

    American journal of hematology 2022; (97(7)):951-965 doi:10.1002/ajh.26579.

    PMID: 35472248
  11. 11

    Late diagnosis: a case of rapidly progressive extranodal NK/T cell lymphoma, nasal type.

    Mori H, Ebisawa K, Nishimura M, Kanazawa K

    BMJ case reports 2018; (2018()) doi:10.1136/bcr-2017-221019.

    PMID: 29455176
  12. 12

    Laryngeal Extranodal Nasal-type Natural Killer/T-cell Lymphoma: A Clinicopathologic Study of 31 Cases in China.

    Xiang CX, Chen ZH, Zhao S, et al.

    The American journal of surgical pathology 2019; (43(7)):995-1004 doi:10.1097/PAS.0000000000001266.

    PMID: 31045893

This page explains ENKTL pathology terminology for educational purposes. Your pathologist and oncologist are the best sources for interpreting your specific biopsy results and report.

Get notified when new evidence is published on Extranodal nasal NK/T cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.